Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance

Charles-Schoeman, ChristinaBuch, Maya H.Dougados, MaximeBhatt, Deepak L.Giles, Jon T.Ytterberg, Steven R.Koch, Gary G.Vranic, IvanaWu, JosephWang, CunshanKwok, KennethMenon, SujathaRivas, Jose L.Yndestad, ArneConnell, Carol A.Szekanecz, Zoltán2022-09-272022-09-272022Annals Of The Rheumatic Diseases. -82 : 1 (2022), p. 119-129. -Ann. Rheum. Dis. - 0003-49670003-4967https://hdl.handle.net/2437/337290Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillancefolyóiratcikkopen access articlehttps://ebib.lib.unideb.hu/ebib/CorvinaWeb?action=cclfind&resultview=long&ccltext=idno+BIBFORM103789OrvostudományokKlinikai orvostudományokhttps://ard.bmj.com/lookup/doi/10.1136/ard-2022-222259http://dx.doi.org/10.1136/ard-2022-2222592022-09-2700085980210000185139865478